Interferon lambda-2 levels in sputum of patients with pulmonary mycobacterium tuberculosis infection

Scandinavian Journal of Immunology

Volumn 80, Issue 1, 2014, Pages 43-49

  Travar, M ^a,b   Vucic, M ^b   Petkovic, M ^a  

^a UNIVERSITY OF BANJA LUKA   (Bosnia and Herzegovina)

^b Health Centre Banja Luka   (Bosnia and Herzegovina)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28A;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; INFLAMMATORY CELL; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SPUTUM;

ADULT; AGED; FEMALE; HUMANS; INTERLEUKINS; LOGISTIC MODELS; MALE; MIDDLE AGED; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 84902687808     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12178     Document Type: Article

References (36)

1. World Health Organization. Global Tuberculosis Report 2013. Geneva, Switzerland. http://www.who.int/tb
2. World Health Organization. Global tuberculosis control: surveillance, planning and financing. WHO/HTM/TB/2009.411. 2009; Geneva, Switzerland.
3. Zuñiga J, Torres-García D, Santos-Mendoza T, Rodriguez-Reyna TS, Granados J, Yunis EY. Cellular and humoral mechanisms involved in the control of tuberculosis. Clin Dev Immunol 2012, 2012:193923.
4. Schwander S, Dheda K. Human lung immunity against Mycobacterium tuberculosis. Am J Respir Crit Care Med 2011;183 :696-707.
5. Cooper AM, Mayer-Barber KD, Sher A. Role of innate cytokines in mycobacterial infection. Mucosal Immunol 2011;4 :252-60.
6. Harding CV, Boom WH. Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors. Nat Rev Microbiol 2010;8 :296-307.
7. Reiling N, Hölscher C, Fehrenbach A et al. Cutting edge: Toll-like receptor (TLR) 2- and TLR4- mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis. J Immunol 2002;169:3480-4.
8. Jo EK. Mycobacterial interaction with innate receptors: TLRs, C-type lectins and NLRs. Curr Opin Infect Dis 2008;21 :279-86.
9. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124 :783-801.
10. Kleinnijenhuis J, Oosting M, Joosten LAB, Netea MG, VanCrevel R. Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol. 2011; 2011:405310.
11. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009;27:393-422.
12. Kotenko SV, Gallagher G, Baurin VV et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4:69-77.
13. Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:63-8.
14. Chen Q, Carroll HP, Gadina M. The newest interleukins: recent additions to the ever-growing cytokine family. Vitam Horm 2006;74:207-28.
15. Coccia EM, Severa M, Giacomini E et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytid and monocyte-derived dendritic cells. Eur J Immunol 2004;34:796-805.
16. Iversen MB, Paludan SR. Mechanisms of type III interferon expression. J Interferon Cytokine Res 2010;30:573-8.
17. Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut 2011;60:1284-93.
18. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartman R. Type III interferon induces a type I IFN like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 2007;81:7749-58.
19. Sommereyns C, Paul S, Staehli P, Michelis T. IFN-λ is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008;4 :e1000017. Published online 2008 March 14.
20. Kotenko SV. IFN-lambdas. Curr Opin Immunol 2011;23 :583-90.
21. Maher SG, Sheikh F, Scarzello AJ et al. IFNα and IFNλ differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 2008;7:1109-15.
22. Zhu H, Buthera M, Nelson DR, Liu C. Novel type IL-28A suppresses hepatitis RNA replication. Virol J 2005;2:80.
23. Marcello T, Grakoui A, Barba-Spaeth G et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131:1887-98.
24. Onoguchi K, Yoneyama M, Takemura A et al. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 2007;282:7576-81.
25. Ank N, Iversen MB, Bartholdy C et al. An important role for type III interferon (IFN-λ/IL-28) in TLR-induced antiviral activity. J Immunol 2008;180:2474-85.
26. Numasaki M, Tagava M, Iwata F et al. IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 2007;178:5086-98.
27. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murikami T. Antitumor activity of IFN-λ in murine tumor models. J Immunol 2006;176:7686-94.
28. Nagarajan U. Induction and function of IFN beta during viral and bacterial infection. Crit Rev Immunol 2011;31 :459-74.
29. Bierne H, Travie L, Mahlakoiv T et al. Activation of type III interferon genes by pathogenic bacteria in infected epithelial cells and mouse placenta. PLoS One 2012;7 :e39080.
30. Pietila TE, Latvala S, Osterlund P, Julkunen I. Inhibition of dynamin-dependent endocytosis interferes with type III IFN expression in bacteria-infected human monocyte-derived DCs. J Leukoc Biol 2010;88 :665-74.
31. Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev 2010;21:237-51.
32. Pfyffer G. Mycobacterium: general characteristics, laboratory detection, and staining procedures. In: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, eds. Manual of Clinical Microbiology, 9th edn. Washington, DC: ASM Press, 2007:543-72. ISBN-10: 1555813712 | ISBN-13: 978-1555813710.
33. Gallagher G, Megjugorac NJ, Yu RY et al. The lambda interferons: guardians of the immune-epithelial interface and the T-helper 2 response. J Interferon Cytokine Res 2010;30:603-15.
34. Li M, Liu X, Zhou Z, Su SB. Interferon-λs: the modulator of antivirus, antitumor and immune responses. J Leukoc Biol 2009;86:23-32.
35. Siebler J, Wirtz S, Weighmann B et al. IL-28A is a key regulator of T-cell-mediated liver injury via T-box transcription factor T-beta. Gastroenterology 2007;132:358-71.
36. Jordan WJ, Eskadale J, Srinivas S et al. Human interferon lambda-1 (IFN-λ1/IL-29) modulates the Th1/Th2 response. Genes Immun 2007;8:254-61.